Debiopharm's Novel IAP Antagonist Debio 1143 Achieves Outstanding Phase II Results for High-Risk Head and Neck Cancer Patients

Monday, September 30, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

Late breaking abstract results presented today at ESMO with chemo-radio sensitizer Debio 1143 present a promising breakthrough strategy to improve the front-line treatment of H&N cancer patients

ESMO 2019 Session Details

Abstract

Presenting investigator

 

Sept. 30th , 10:15amCordoba Auditorium (Hall 7)

 

Preferred Paper – Head and neck cancer

 

 

LBA65 - Double-blind Randomized Phase 2 Results Comparing Concurrent Highdose Cisplatin Chemorradiation (CRT) plus Debio 1143 or Placebo In High-risk Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN): A GORTEC Study

 

Prof. Jean Bourhis,

Head of the Radio-Oncology Department CHUV, Lausanne, Switzerland, Lead study author



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store